SAN FRANCISCO, Nov. 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc, a
private start-up pharmaceutical company committed to addressing the unmet
medical needs of patients with life-threatening inflammatory diseases,
announced that David E. Thompson has been appointed to the Company's Board of
Directors. Mr. Thompson brings his corporate strategy and alliance management
expertise to Anthera as the Company enters an important phase of development.
"David brings an extraordinary complement of pharmaceutical operations and
alliance management experience to Anthera," said Lowell E. Sears, chairman of
the Board of Directors for Anthera Pharmaceuticals. "David's more than
30 years of pharmaceutical industry experience from Eli Lilly and Company will
provide additional leadership in our product development and in-licensing
"Our strategy to in-license compounds for the treatment of
life-threatening inflammatory diseases dovetails perfectly with David's
experience at Eli Lilly and Company. He has successfully stewarded many
corporate and product partnerships and joins Anthera at the moment we are
preparing to finalize our licensing efforts," commented Paul F. Truex,
President and Chief Executive Officer of Anthera Pharmaceuticals.
Mr. Thompson joins four other distinguished members of Anthera's Board of
Directors. In addition to Mr. Sears, chairman, and Mr. Truex, President and
CEO, the other board members are: Christopher S. Henney, a co-founder of
three major publicly held U.S. biotechnology companies and has been associated
with the formation of several others; and Dennis M. Lanfear, president of
Lanfear Capital Advisors, LLC and formerly corporate officer and
vice-president at Amgen.
About David E. Thompson
David E. Thompson, now retired, was named vice president of corporate
strategy business development, the ventures group, and alliance management for
Eli Lilly and Company in January 2001. Prior to that, Mr. Thompson served as
vice president of corporate business development for Eli Lilly and Company.
Mr. Thompson joined Eli Lilly in 1971, and throughout the 1970s, held numerous
positions in sales, marketing research, sales management, and new product
planning and licensing. He was named president and general manager of Eli
Lilly Canada, a Lilly affiliate, in November 1985 and president/CEO of IVAC
Corporation, a medical device subsidiary in December 1986. He served as vice
president of pharmaceutical product management and licensing from 1988-1992.
Born in Lansing, Michigan, he received Bachelor of Science (BS) and Master of
Business Administration (MBA) degrees from Michigan State University.
Mr. Thompson retired from Eli Lilly and Company in July 2005 and currently
serves as a member of the Board of Directors for a select group of
pharmaceutical companies including Bayhill Therapeutics, Inc. and Anthera
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately held pharmaceutical company
committed to world-class development and commercialization of promising
clinical products to address the unmet medical needs of patients with
life-threatening inflammatory diseases. Anthera has identified a number of
novel clinical stage and late stage pre-clinical anti-inflammatory products
which have the potential to address a variety of inflammatory diseases
including: Acute Lung Injury, Acute Respiratory Distress Syndrome, Acute
Chest Syndrome, Acute Coronary Syndrome, Atherosclerosis, Chronic Obstructive
Pulmonary Disease and Psoriasis.
In order to efficiently commercialize this platform, Anthera has formed a
management team with extensive experience in licensing, clinical research,
development, and commercialization of anti-inflammatory products. Anthera's
focus is to bring products with promising commercial potential onto the market
in the near term. To date Anthera has raised approximately $1M of seed
funding from Sears Capital Management and Lanfear Capital to complete its
initial in-licensing activities. Please visit Anthera Pharmaceuticals at
Laura Silver, LAS Communications, Inc.
SOURCE Anthera Pharmaceuticals